Second Sight Medical Products' Argus II Retinal Prosthesis System
Industryweek 3668 Eyeball
Industryweek 3668 Eyeball
Industryweek 3668 Eyeball
Industryweek 3668 Eyeball
Industryweek 3668 Eyeball

Bionic Eye Gives Hope to the Blind

Feb. 6, 2013
Consisting of 60 electrodes implanted in the retina and glasses fitted with a special mini camera, Argus II has already won the approval of European regulators. The U.S. Food and Drug Administration is soon expected to follow suit, making this bionic eye the world's first to become widely available.

WASHINGTON -- After years of research, the first bionic eye has seen the light of day in the United States, giving hope to the blind around the world.

Developed by Second Sight Medical Products, the Argus II Retinal Prosthesis System has helped more than sixty people recover partial sight, with some experiencing better results than others.

Consisting of 60 electrodes implanted in the retina and glasses fitted with a special mini camera, Argus II has already won the approval of European regulators. The U.S. Food and Drug Administration is soon expected to follow suit, making this bionic eye the world's first to become widely available.

"It's the first bionic eye to go on the market in the world, the first in Europe and the first one in the U.S.," said Brian Mech, the California-based company's vice president of business development.

Those to benefit from Argus II are people with retinitis pigmentosa, a rare genetic disease, affecting about 100,000 people in the U.S., that results in the degeneration of the retinal photoreceptors.

The photoreceptor cells convert light into electrochemical impulses that are transmitted to the brain via the optic nerve, where they are decoded into images.

"The way the prosthesis works [is] it replaces the function of the photoreceptors," Mech told AFP.

Thirty people aged 28 to 77 took part in the clinical trial for the product, all of whom were completely blind.

Mech said the outcomes varied by participant.

"We had some patients who got just a little bit of benefit and others who could do amazing things like reading newspaper headlines," he said.

In some cases, the subjects could even see in color.

"Mostly they see in black and white, but we have demonstrated more recently we can produce color vision as well," Mech said.

The High Cost of Sight

According to Mech, Argus II is already available in several European countries for 73,000 euros ($99,120). A U.S. price has not been set but is likely to be higher, he said.

"Now we are (at) around 60 patients... We have tons of surgeries scheduled, the number is growing almost daily," he said.

Other researchers are also vying to develop bionic eyes of their own, that would offer higher resolution images with more electrodes implanted in the retina.

At the Massachusetts Institute of Technology, a team lead by John Wyatt is working on a system that would have up to 400 electrodes.

Daniel Palanker of California's Stanford University is proposing a different approach based on tiny photovoltaic cells instead of electrodes.

"We're thinking about implanting up to 5,000 of these cells at the back of the eye that would theoretically allow for a resolution that is ten times better," George Goetz, a member of Palanker's team, told AFP. This system would also help individuals who lost their sight due to age-related macular degeneration, he added.

These photovoltaic cells convert light into electrical impulses that stimulate the nerve cells in the retina, which then transmit the signals to the brain.

This system has successfully been tested in rats, and the first clinical trial could begin in a year, probably in France. Palanker is linked with French company Pixium Vision based in Paris.

Grace Shen, of the National Eye Institute that has supported both the Argus and Palanker projects, said work on stem cells and optogenetics were also important areas to focus on in developing treatments or the prevention of blindness. Through optogenetics, retina cells can be genetically modified to render them light-sensitive again.

"I think the bionic eye is something that is going to work in some patients and is not going to work with all patients, but it's an exciting time ahead," said Grace Shen of the National Eye Institute that has supported both the Argus and Palanker projects.

"We know it's feasible, it can work, but we still have a long way to go."

- Jean-Louis Santini, AFP

Copyright Agence France-Presse, 2013

Popular Sponsored Recommendations

Empowering the Modern Workforce: The Power of Connected Worker Technologies

March 1, 2024
Explore real-world strategies to boost worker safety, collaboration, training, and productivity in manufacturing. Emphasizing Industry 4.0, we'll discuss digitalization and automation...

3 Best Practices to Create a Product-Centric Competitive Advantage with PRO.FILE PLM

Jan. 25, 2024
Gain insight on best practices and strategies you need to accelerate engineering change management and reduce time to market. Register now for your opportunity to accelerate your...

Transformative Capabilities for XaaS Models in Manufacturing

Feb. 14, 2024
The manufacturing sector is undergoing a pivotal shift toward "servitization," or enhancing product offerings with services and embracing a subscription model. This transition...

Shifting Your Business from Products to Service-Based Business Models: Generating Predictable Revenues

Oct. 27, 2023
Executive summary on a recent IndustryWeek-hosted webinar sponsored by SAP

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!